Novirio plans to do clinical trials in China for its hepatitis B treatment. Though developing nations are not generally considered capable of generating quality data, Novirio is betting that close management will yield data it can submit to FDA and leverage in Asia, where most of the patient population resides. It's a move to boost marketability against a competing drug from Glaxo.
Can the location of clinical trials boost a drug's salability? Novirio Pharmaceuticals Ltd. of Cambridge, MA thinks so—if the clinical trials yield data that a company can leverage in marketing.
Novirio, developing a nucleoside called LdT (ß-L-2'-deoxythymidine) as a treatment for hepatitis B, says it aims to take advantage of...
Create an account to read this article
Already a subscriber?
Private Company Edition: Flagship’s Lila secures big series A cash six months after $200m seed funding announced in March. Also, Reunion Neuroscience increases its series A to $133m, Dualitas launches with $65m and Tasca grows its series A to $67m as its lead drug enters Phase I/II.
Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.
About four months after GSK paid $1.2bn up front for another FGF21 analog in MASH, Roche looks to buy 89Bio, adding Phase III pegozafermin to its growing cardiometabolic pipeline.
Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.
Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.
